Home / Health / Taiwan Drug Sparks Global Blood Cancer Hope
Taiwan Drug Sparks Global Blood Cancer Hope
3 Nov
Summary
- Ropeg approved for essential thrombocythemia in Taiwan, Japan, US, and China.
- European approval for ET remains pending, showing a regional access gap.
- Drug shows superior response rate compared to existing ET therapy.
PharmaEssentia's blood cancer treatment, ropeginterferon alfa-2b (Ropeg), has achieved essential thrombocythemia (ET) approvals in Taiwan, Japan, the United States, and China. This broadens treatment avenues for individuals managing this chronic condition.
Despite these successes, Ropeg's ET indication is not yet approved in Europe, highlighting a disparity in patient access across different global markets. The drug, developed by Taiwan-based PharmaEssentia Corporation, is already approved for polycythemia vera (PV) in approximately 50 nations worldwide.
PV and ET are serious blood cancers known as myeloproliferative neoplasms (MPNs). They are characterized by an overproduction of blood cells, posing risks of blood clots and potential progression to more severe conditions. Current treatments aim to manage blood cell counts and improve patient quality of life.
Clinical evidence suggests Ropeg's potential to modify the underlying disease. In the global Phase III SURPASS-ET trial for ET, Ropeg demonstrated a significantly higher durable clinical response rate than anagrelide, a recognized therapy for platelet overproduction. These findings were recognized at major hematology conferences in 2025 and 2026.
While Ropeg received European Union approval for PV in 2019, European patients are still awaiting access for ET. This situation sharpens the focus on the region's regulatory timelines, particularly given the drug's approval in other major markets. A 2009 licensing agreement dictates that AOP Orphan Pharmaceuticals GmbH is responsible for Ropeg's development and commercialization in Europe.
PharmaEssentia, retaining core technologies and intellectual property, manufactures Ropeg for global supply from its EU Good Manufacturing Practice-certified facility in Taichung, Taiwan. The company is committed to expanding patient access as Ropeg's clinical evidence and approved uses continue to grow, aiming to ensure consistent availability of the treatment.
